TechneScan sales to start in Sweden

Article

Radiopharmaceutical developer Mallinckrodt Medical said that itwill begin sales in Sweden of TechneScan Q12, a technetium-basedcardiac imaging agent, following approval of the agent by Sweden'shealth authorities. Sweden is the first country in the

Radiopharmaceutical developer Mallinckrodt Medical said that it

will begin sales in Sweden of TechneScan Q12, a technetium-based

cardiac imaging agent, following approval of the agent by Sweden's

health authorities. Sweden is the first country in the European

Union to approve TechneScan, and certifications in other European

nations are expected. St. Louis-based Mallinckrodt filed a new

drug application for the product in the U.S. in 1994.

Recent Videos
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Related Content
© 2025 MJH Life Sciences

All rights reserved.